HighTide Therapeutics places big IPO bet on “affluenza” drug
The company is pouring almost all its R&D budget into producing a metabolic drug to treat several conditions including diabetes Key Takeaways: With no products yet on the market, HighTide…
FAST NEWS: MicroPort MedBot Revenue Soars in First Full Year of Product Sales
The latest: Surgical robot maker Shanghai MicroPort MedBot (Group) Co. Ltd. (2522.HK) said on Wednesday its revenue jumped by more than 850% last year, while it recorded a net loss…
FAST NEWS: CStone Revenue Doubles, Helping Company Pare Losses
The latest: CStone Pharmaceuticals (2616.HK) announced on Thursday it expects to report its revenue doubled to 475 million yuan ($70 million) or more last year, while its net loss narrowed…
FAST NEWS: InnoCare Pharma Sees Losses Shrinking, But Stock Still Slumps
The latest: Drug maker InnoCare Pharma Ltd. (9969.HK) announced Wednesday evening that it expects to report a net loss of up to 100 million yuan ($15.7 million) for all 2021,…
RELATED ARTICLES
-
Innogen Pharma jostles for a slice of the weight-loss market
- PegBio aims to bulk up its finances to deliver weight-loss drugs
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- IPO pitch puts BrainAurora’s earnings under the microscope
